Cargando…
The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A retrospective analysis
OBJECTIVE: Sulfonylureas have historically been analyzed as a medication class, which may be inappropriate given the differences in properties inherent to the individual sulfonylureas (hypoglycemic risk, sulfonylurea receptor selectivity, and effects on myocardial ischemic preconditioning). The purp...
Autores principales: | Pantalone, Kevin M., Kattan, Michael W., Yu, Changhong, Wells, Brian J., Arrigain, Susana, Jain, Anil, Atreja, Ashish, Zimmerman, Robert S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875427/ https://www.ncbi.nlm.nih.gov/pubmed/20215447 http://dx.doi.org/10.2337/dc10-0017 |
Ejemplares similares
-
Response to Comment on: Pantalone et al. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A Retrospective Analysis. Diabetes Care 2010;33:1224–1229
por: Pantalone, Kevin M., et al.
Publicado: (2011) -
Comment on: Pantalone et al. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A Retrospective Analysis. Diabetes Care 2010;33:1224–1229
por: Khalangot, Mykola D.
Publicado: (2011) -
Glycemic Control and Hypoglycemia in Veterans Health Administration Patients Converted from Glyburide to Glipizide
por: Skoff, Rachel A., et al.
Publicado: (2011) -
Glycemic Control Was Unchanged in Veterans Health Administration Patients Converted from Glyburide to Glipizide
por: Aspinall, Sherrie L., et al.
Publicado: (2012) -
Predicting 6-Year Mortality Risk in Patients With Type 2 Diabetes
por: Wells, Brian J., et al.
Publicado: (2008)